R.S. Jensen et al. / Journal of Organometallic Chemistry 692 (2007) 286–294
291
31.2 (s), 34.6 (s), 36.8 (s), 40.1 (s), 56.6 (s), 115.9 (s), 121.3
(s), 121.5 (virtual triplet, Japp = 11 Hz), 122.1 (q,
J = 321 Hz, OTf), 125.8 (t, J = 6 Hz), 132.1 (t, J = 2 Hz),
155.0 (m, J = 72, 36 Hz), 159.2 (t, J = 2 Hz), 159.6 (s),
164.9 (t, J = 2 Hz), 167.9 (m). 31P{1H} NMR (CD3CN,
20 ꢁC): d 127.3 (s). IR (KBr): 2324, 2296 cmꢀ1 (mC„N).
Compound 1c: Mp 136–138 ꢁC (dec). 1H NMR
(CD3CN, 20 ꢁC): d 1.45 (s, 18H), 1.70 (s, 36H), 7.01 (d,
J = 8.1 Hz, 4H), 7.43 (t, J = 8.4 Hz, 4H), 7.80 (virtual trip-
let, J = 2.8 Hz, 4H). 13C{1H} NMR (CD3CN, 20 ꢁC): d
31.0 (s), 34.8 (s), 36.7 (s), 40.1 (s), 120.0 (virtual triplet,
Japp = 12 Hz), 121.9 (q, J = 320 Hz, OTf), 124.2 (q,
J = 271 Hz, CF3), 126.0 (t, J = 6 Hz), 126.9 (q, J = 4 Hz),
129.7 (t, J = 2 Hz), 132.0 (s), 133.7 (q, J = 33 Hz), 155.0
(m, J = 88, 53 Hz), 159.2 (t, J = 2 Hz), 160.0 (s), 165.7
(m, J = 50, 46 Hz). 31P{1H} NMR (CD3CN, 20 ꢁC): d
143.1 (s). IR (KBr): 2324, 2298 cmꢀ1 (mC„N).
sure. The resulting solid was recrystallized from CH2Cl2/
Et2O to give 2a as dark red crystals, suitable for X-ray dif-
fraction analysis (185 mg, 85%).
1
Compound 2a: H NMR (CD3CN, 20 ꢁC): d 1.42 (s,
18H), 1.72 (s, 36H), 6.77 (d, J = 7.8 Hz, 4H), 6.94 (t,
J = 7.5 Hz, 4H), 7.19 (t, J = 7.5 Hz, 2H), 7.64 (virtual trip-
let, Japp = 1.7 Hz, 4H). 13C{1H} NMR (CD3CN, 20 ꢁC): d
31.5 (s), 34.4 (s), 36.2 (s), 39.6 (s), 124.3 (t, J = 4 Hz), 125.9
(m), 128.0 (s), 129.6 (s), 130.7 (s), 131.7 (s), 147.7 (m,
J = 64, 35 Hz), 155.3 (s). 157.3 (s), 163.3 (m, J = 89,
10 Hz). 31P{1H} NMR (CD3CN, 20 ꢁC): d 162.4 (d,
J = 228 Hz). IR (KBr): 2316, 2279 cmꢀ1 (mC„N). Anal.
Calc. for C57H74F3N2O3P2RhS Æ CH2Cl2: C, 59.34; H,
6.52; N, 2.39. Found: C, 59.91; H, 6.55; N, 2.37%.
1
Compound 2b: H NMR (CD3CN, 20 ꢁC): d 1.44 (s,
18H), 1.73 (s, 36H), 3.68 (s, 6H), 6.48 (d, J = 9.0 Hz,
4H), 6.71 (d, J = 9.0 Hz, 4H), 7.66 (s, 4H, PAr). 13C{1H}
NMR (CD3CN, 20 ꢁC): d 31.5 (s), 34.4 (s), 36.2 (s), 39.7
(s), 56.1 (s), 115.0 (s), 124.3 (t, J = 4 Hz), 124.4 (s), 126.2
(m), 129.9 (s), 146.8 (m, J = 64, 35 Hz), 155.1 (s), 157.4
(s), 161.5 (s), 164.2 (m, J = 90, 10 Hz). 31P{1H} NMR
(CD3CN, 20 ꢁC): d 154.7 (d, J = 228 Hz). IR (KBr):
2314, 2285 cmꢀ1 (mC„N).
Compound 1d: Mp 127–129 ꢁC (dec). 1H NMR
(CD3CN, 20 ꢁC): d 1.46 (s, 18H), 1.70 (s, 36H), 6.94 (d,
J = 7.9 Hz, 4H), 7.14 (t, J = 7.9 Hz, 4H), 7.44 (t,
J = 7.5 Hz, 2H), 7.79 (virtual triplet, Japp = 2.7 Hz, 4H).
13C{1H} NMR (CD3CN, 20 ꢁC): d 31.1 (s), 34.7 (s), 36.7
(s), 40.0 (s), 120.6 (virtual triplet, Japp = 12 Hz), 125.7 (t,
J = 6 Hz), 128.6 (s), 129.2 (t, J = 3 Hz), 130.1 (s), 134.3
(s), 156.2 (m, J = 82, 47 Hz), 159.0 (t, J = 2 Hz), 159.7
(s), 167.0 (m, J = 51, 47 Hz). 31P{1H} NMR (CD3CN,
20 ꢁC): d 135.8 (s). IR (KBr): 2332, 2303 cmꢀ1 (mC„N).
Anal. Calc. for C56H74B2F8N2P2Pd: C, 60.21; H, 6.68; N,
2.51. Found: C, 60.39; H, 6.61; N, 2.53%.
1
Compound 2c: H NMR (CD3CN, 20 ꢁC): d 1.42 (s,
18H), 1.73 (s, 36H), 6.87 (d, J = 8.1 Hz, 4H), 7.24 (d,
J = 8.1 Hz, 4H), 7.65 (virtual triplet, Japp = 1.5 Hz, 4H).
13C{1H} NMR (CD3CN, 20 ꢁC): d 31.4 (s), 34.5 (s), 36.2
(s), 39.7 (s), 124.5 (t, J = 4 Hz), 124.9 (q, J = 271 Hz,
CF3), 125.4 (m), 126.5 (q, J = 3 Hz), 128.3 (s), 130.8 (q,
J = 32 Hz), 135.3 (s), 146.3 (dd, J = 63, 33 Hz), 155.6 (s),
157.4 (s), 162.9 (m). 31P{1H} NMR (CD3CN, 20 ꢁC): d
168.6 (d, J = 230 Hz). IR (KBr): 2321, 2286 cmꢀ1 (mC„N).
Anal. Calc. for C59H72F9O3N2P2RhS: C, 57.84; H, 5.92;
N, 2.29. Found: C, 57.28; H, 6.03; N, 2.20%.
1
Compound 1e: Mp 69–70 ꢁC (dec). H NMR (CD3CN,
20 ꢁC): d 1.43 (s, 18H), 1.68 (s, 36H), 6.93 (d, J = 7.7 Hz,
4H), 7.11 (t, J = 7.9 Hz, 4H), 7.39 (t, J = 7.5 Hz, 2H),
7.64 (s, 8H), 7.71 (s, 16H), 7.78 (virtual triplet,
Japp = 2.7 Hz, 4H). 13C{1H} NMR (CD3CN, 20 ꢁC): d
31.1 (s), 34.7 (s), 36.7 (s), 40.0 (s), 118.5 (qui, J = 4 Hz),
120.6 (virtual triplet, Japp = 12 Hz), 125.3 (q, J = 272 Hz,
CF3), 125.8 (t, J = 6 Hz), 128.6 (s), 129.3 (t, J = 2 Hz),
129.7 (qq, J = 32, 3 Hz), 130.1 (s), 134.3 (s), 135.4 (s),
156.4 (m, J = 81, 46 Hz), 159.0 (t, J = 2 Hz), 159.8 (s),
162.4 (q, JBC = 50 Hz; septet, JBC = 17 Hz), 167.1(m,
J = 51, 46 Hz). 31P{1H} NMR (CD3CN, 20 ꢁC): d 135.6
(s). IR (KBr): 2332, 2303 cmꢀ1 (mC„N). Anal. Calc. for
4.4. Preparation of [Rh(diene)2(DPCB–Y)]OTf (2d,e)
The preparation of 2d (diene = 1,5-cyclooctadiene) is
given as a representative example. A 25 mL Schlenk tube
was charged with [Rh(l-Cl)(cod)]2 (60 mg, 0.122 mmol),
DPCB (184 mg, 0.244 mmol) and CH2Cl2 (2 mL), forming
a homogeneous solution. After 20 min, AgOTf (65 mg,
0.253 mmol) was added, and the solution was stirred for
1 h. Removal of silver salts by filtration through a Celite-
padded glass filter, followed by evaporation of solvent
under reduced pressure provided crude product as a purple
solid, which was washed with Et2O, and then recrystallized
from THF/Et2O affording the desired complex as a dark
red crystalline solid (197 mg, 70%). Complex 2e was simi-
larly prepared from [Rh(l-Cl)(nbd)]2 in 49% yield.
C
120H98 B2F48N2P2Pd: C, 53.98; H, 3.70; N, 1.05. Found:
C, 54.08; H, 3.70; N, 1.08%.
4.3. Preparation of [Rh(MeCN)2(DPCB–Y)]OTf (2a–c)
A typical procedure is reported for 2a. To a solution of
[Rh(l-Cl)(cyclooctene)2]2 (70 mg, 0.1 mmol) in CH2Cl2
(5 mL) was added DPCB (150 mg, 0.2 mmol). After stir-
ring at ambient temperature for 2 h, solvent was removed
under reduced pressure to provide [Rh(l-Cl)(DPCB)]2 as
a black precipitate. This product was dissolved in CH2Cl2
(2 mL), then MeCN (100 lL, 2 mmol) and AgOTf
(52 mg, 0.2 mmol) were added. After stirring for 2 h, the
solution was filtered through a Celite-padded glass filter
to remove silver salts and concentrated under reduced pres-
Compound 2d: 1H NMR (CDCl3, 20 ꢁC): d 1.41 (s,
18H), 1.61 (s, 36H), 2.41 (s, 8H), 5.26 (s, 4H), 7.00 (m,
8H), 7.27 (m, 2H), 7.65 (d, J = 2.4 Hz). 13C{1H} NMR
(CDCl3, 20 ꢁC): d 30.4 (s), 31.1 (s), 34.5 (s), 35.4 (s), 39.5
(s), 96.3 (m), 121.0 (q, J = 321 Hz, OTf), 122.0 (d,
J = 5 Hz), 124.9 (t, J = 4.1 Hz), 128.4 (m), 128.6 (s),
129.4 (s), 131.4 (s), 150.8 (dd, J = 59, 32 Hz), 154.8 (s),